HTLD Stock DD Heartland Express, Inc. 09/12/2014 14:18:36

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
HTLD Heartland Express, Inc. $HTLD Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=HTLD&...mp;yt0=Go!

Last Updated: 09/12/2014 14:18:32

Current Price and Quotes
Last Price 24.51
Previous Close 24.07 Open 24.15
Daily Range 24.08 - 24.64 52wk Range 13.74 - 24.42
Volume 333,405 Dividend 0.08
Average Vol (30d) 296,657 Yield 0.326397




Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 582,257 545,745 528,623 499,516
Cost of Revenue 236,424 227,089 215,704 177,216
Gross Profit 345,833 318,656 312,919 322,300
Operating Expenses

Research and Development - - - -
Sales, General and Admin. 197,893 181,706 181,269 182,219
Non-Recurring Items - - - -
Other 68,908 57,158 57,226 61,949
Operating Income 112,302 94,901 106,557 91,449
Income From Continuing Operations

Add'l Income/Expense Items 33,732 15,783 32,906 14,741
Earnings Before Interest and Tax 112,764 95,575 107,330 92,873
Interest Expense 208 - - -
Earnings Before Tax 112,556 95,575 107,330 92,873
Income Tax 41,974 34,034 37,398 30,657
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 70,582 61,541 69,932 62,216
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 70,582 61,541 69,932 62,216
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 70,582 61,541 69,932 62,216

Recent News

Sep 8, 2014 Heartland Express, Inc. Declares Regular Quarterly Dividend
Jul 22, 2014 Heartland Express, Inc. Reports Revenues and Earnings for the Second Quarter of 2014



HTLD Heartland Express, Inc. Research DD Guide

Stock Message Board http://investorshangout.com/search?q=HTLD&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/HTLD/quote
Stock Chart http://www.otcmarkets.com/stock/HTLD/chart
Company Info http://www.otcmarkets.com/stock/HTLD/company-info
Recent News http://www.otcmarkets.com/stock/HTLD/news
Financials http://www.otcmarkets.com/stock/HTLD/financials
Filings and Disclosure http://www.otcmarkets.com/stock/HTLD/filings
Short Sales http://www.otcmarkets.com/stock/HTLD/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/HTLD/insider-transactions
Research Reports http://www.otcmarkets.com/stock/HTLD/research
Summary http://finance.yahoo.com/q?s=HTLD
Historical Prices http://finance.yahoo.com/q/hp?s=HTLD+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=HTLD
Basic Chart http://finance.yahoo.com/q/bc?s=HTLD+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=HTLD+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=HTLD+Headlines
Press Releases http://finance.yahoo.com/q/p?s=HTLD+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=HTLD+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=HTLD+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=HTLD+Industry
Major Holders http://finance.yahoo.com/q/mh?s=HTLD+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=HTLD+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=HTLD+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=HTLD
Balance Sheet http://finance.yahoo.com/q/bs?s=HTLD
Cash Flow http://finance.yahoo.com/q/cf?s=HTLD+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/HTLD
Market Watch http://www.marketwatch.com/investing/stock/HTLD
Bloomberg http://www.bloomberg.com/quote/HTLD:US
Morningstar http://quotes.morningstar.com/stock/s?t=HTLD
Bussinessweek http://investing.businessweek.com/research/st...icker=HTLD
Barchart http://www.barchart.com/quotes/stocks/HTLD
OTC Short Report http://otcshortreport.com/index.php?index=HTLD
Investopedia http://www.investopedia.com/markets/stocks/HTLD/?wa=0
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 29

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 23

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 17

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 16

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 22

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 23

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading

Top 5 Most Recently Viewed Articles

Context Therapeutics Gains Confidence with Strategic Developments

Updated Category News Views 60

Piper Sandler's Renewed Confidence in Context Therapeutics Piper Sandler has reiterated an Overweight rating for Context Therapeutics (NASDAQ: CNTX), maintaining a price target of $4.50 for the stock. This endorsement underscores their belief in the company’s potential within the biopharmaceutical sector. Positive Data from Competitors Enhances Expectations This renewed...

Continue Reading
Actinium's ATNM-400: A Promising Frontier in Prostate Cancer Therapy

Updated Category News Views 167

Introduction to ATNM-400's Innovative Approach Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) has announced compelling preclinical data showcasing its innovative treatment, ATNM-400. This first-in-class antibody radioconjugate targets a unique, non-PSMA antigen, revolutionizing prostate cancer therapy. ATNM-400 offers noteworthy therapeutic activity independent of...

Continue Reading
Opportunity Knocks: Ligon's Major Auction Up for Bids

Updated Category News Views 17

Equipment Auction Offers Unique Buying Opportunity Catch this: Ligon Co.'s auction is like finding a needle in a haystack in a world of overpriced equipment. We're talking about a smorgasbord of heavy machinery up for online grabs, and it’s happening until June 17. Auction Highlights: Your Next Business Asset? From telehandlers to trailers, this ain't your everyday yard...

Continue Reading
Selector Enhances Service Delivery with AWS Marketplace Launch

Updated Category News Views 147

Selector Launches on AWS Marketplace for Better Accessibility Selector, a pioneer in AI-driven observability and network intelligence, is transforming how organizations manage their network operations. The company has launched its flagship platform on the Amazon Web Services (AWS) Marketplace, which makes it easier for customers to procure and deploy its powerful AI tools...

Continue Reading
Exploring the Surge in Decentralized Energy Storage Growth

Updated Category News Views 229

Decentralized Energy Storage Market Overview The Decentralized Energy Storage market is gaining remarkable traction, with significant insights indicating a shift towards sustainable energy solutions. Valued at approximately USD 10.88 billion, the market is anticipated to expand to a staggering USD 35.62 billion, exhibiting a compound annual growth rate (CAGR) of 15.98%...

Continue Reading